<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327791</url>
  </required_header>
  <id_info>
    <org_study_id>1579493</org_study_id>
    <nct_id>NCT04327791</nct_id>
  </id_info>
  <brief_title>COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)</brief_title>
  <acronym>COMBO 1</acronym>
  <official_title>COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bassett Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Viroclinics Biosciences B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bassett Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed&#xD;
      trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented&#xD;
      patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the&#xD;
      combination treatment group (oseltamivir and baloxavir); Group 2, the standard treatment&#xD;
      group (oseltamivir and placebo).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 60 hospitalized patients with laboratory confirmed influenza who provide informed&#xD;
      consent and meet trial inclusion/exclusion criteria.&#xD;
&#xD;
      Experimental Design and Methods In a randomized, double-blind, placebo-controlled Phase&#xD;
      2-like, investigator-directed trial, hospitalized patients with laboratory confirmed&#xD;
      influenza meeting inclusion and exclusion criteria, will be provided information on the&#xD;
      trial, offered enrollment, and enrolled randomly in a 1:1 ratio to one of two groups upon&#xD;
      signing of the study's informed consent form: Group 1, the combination treatment group&#xD;
      (oseltamivir and baloxavir); Group 2, the standard treatment group (oseltamivir and placebo).&#xD;
&#xD;
        -  Group 1, the combination treatment group will receive oseltamivir and baloxavir&#xD;
&#xD;
             -  Oseltamivir: 75 mg po bid for 5 days&#xD;
&#xD;
             -  Baloxavir: 40 mg po once for wt &lt; 80 kg OR 80 mg po once for wt &gt;/= 80 kg&#xD;
&#xD;
        -  Group 2, the standard treatment group will receive oseltamivir and placebo&#xD;
&#xD;
             -  Oseltamivir: 75 mg po bid for 5 days&#xD;
&#xD;
             -  Placebo: Once&#xD;
&#xD;
      Oseltamivir dosing may be reduced for patients with decreased renal function as follows, per&#xD;
      treating physician:&#xD;
&#xD;
        -  CrCl &gt; 60 mL/minute: No dosage adjustment&#xD;
&#xD;
        -  CrCl &gt; 30 to 60 mL/minute: 30 mg po bid&#xD;
&#xD;
        -  CrCl &gt; 10 to 30 mL/minute: 30 mg po qd&#xD;
&#xD;
        -  HD: 30 mg po once and 30 mg po after each HD session&#xD;
&#xD;
        -  CAPD: 30 mg po once&#xD;
&#xD;
        -  CRRT: 30 mg po qd After assignment of a unique study number after signing informed&#xD;
           consent, baseline data will be collected at time 0 including personal and clinical&#xD;
           information and protocol directed laboratory specimens - nasal swabs for influenza PCR&#xD;
           for patients who only had a rapid antigen test and blood specimens for patients who&#xD;
           consent to additional blood drawing (for improved efficacy and safety analyses; not&#xD;
           required for enrollment). Patients will be given oseltamivir by their healthcare&#xD;
           providers. Research personnel's only involvement for oseltamivir dosing will be to&#xD;
           remind providers that earlier treatment improves efficacy. Patients will then be given a&#xD;
           single dose of baloxavir or placebo by the study's CRC as per a computerized random&#xD;
           allocation scheme with dose determined by weight (as above); the CRC will notify the&#xD;
           patient's provider that the patient has been given the single (blinded) dose. At time 1,&#xD;
           2, 3, 4, 7, and 30 days, nasal swabs will again be obtained, clinical information will&#xD;
           be obtained from the patient via interview and review of the EMR, and blood specimens&#xD;
           for patients who consented to additional blood drawing. Follow up will continue for 30&#xD;
           days.&#xD;
&#xD;
      Efficacy and adjudicated safety data points will be assessed by a blinded Data Monitoring&#xD;
      Committee (DMC) after completion of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Clearance of Viral Shedding</measure>
    <time_frame>30 days</time_frame>
    <description>influenza viral titer obtained by nasal swab using qCulture</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>baloxavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baloxavir: 40 mg po once for wt &lt; 80 kg OR 80 mg po once for wt &gt;/= 80 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo po once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baloxavir</intervention_name>
    <description>administered PO once</description>
    <arm_group_label>baloxavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>administered PO once</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Adults &gt;/= 18 years old&#xD;
&#xD;
          2. Laboratory confirmed influenza A and/or B (rapid test or PCR)&#xD;
&#xD;
          3. Able to be enrolled, randomized, and dosed with study drug within 8 hours of the&#xD;
             decision to admit patient to hospital for treatment of influenza&#xD;
&#xD;
          4. Oseltamivir treatment ordered or started by clinical team&#xD;
&#xD;
          5. Able to and provide written informed consent&#xD;
&#xD;
          6. Able to commit to 30 days of follow up&#xD;
&#xD;
          7. Weight &gt; 40 kg&#xD;
&#xD;
          8. SARS-CoV-2 PCR swab sent within 1 week of enrollment&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. ESRD not undergoing hemodialysis (HD) or peritoneal dialysis (CAPD)&#xD;
&#xD;
          2. Severe hepatic insufficiency, cirrhosis, acute or chronic liver failure&#xD;
&#xD;
          3. Nausea/vomiting, aspiration risk, or other conditions precluding the ability to use&#xD;
             oral medications (if patient is NPO including meds) unless gastric tube use available&#xD;
             (e.g., NG tube, G tube, etc.)&#xD;
&#xD;
          4. Influenza medication use within the prior week, other than the initial oseltamivir&#xD;
             given during this hospitalization for this episode of influenza&#xD;
&#xD;
          5. Oseltamivir or baloxavir allergy or intolerance&#xD;
&#xD;
          6. Pregnancy (need negative pregnancy test (urine or blood) in reproductive age women)&#xD;
&#xD;
          7. Absence of dependable contraception in reproductive age women&#xD;
&#xD;
          8. Inability to obtain informed consent&#xD;
&#xD;
          9. Refusal of oseltamivir therapy by patient as baseline treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Freilich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bassett Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jennifer Victory, RN</last_name>
    <phone>6075476965</phone>
    <email>jennifer.victory@bassett.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Freilich, MD</last_name>
    <phone>6075474586</phone>
    <email>daniel.freilich@bassett.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bassett Medical Center</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jennifer Victory, RN</last_name>
      <phone>607-547-6965</phone>
      <email>jennifer.victory@bassett.org</email>
    </contact>
    <investigator>
      <last_name>daniel freilich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bassett Healthcare</investigator_affiliation>
    <investigator_full_name>Daniel Freilich, MD</investigator_full_name>
    <investigator_title>attending physician - hospitalist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Baloxavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

